Objective Response Rate (ORR)
1 clinical trials · Condition
◉ Watch Objective Response Rate (ORR)
| Record | Firm | Date |
|---|---|---|
| Envafolimab, Lenvatinib Combined With TACE in the Treatment of Unresectable Locally Advanced Hepatocellular Carcinoma (NCT05582109) | Tianjin Medical University Cancer Institute and Hospital | 2022-10-30 |
Track Objective Response Rate (ORR) automatically
Every clearance here is in the API, with alerts when new ones post.